Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192181 | 1.00 | CA1 (0.40) | CA1CA2PEPDZDHHC7LTA4H | |
| SCHEMBL18109682 | 1.00 | CA1 (0.40) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL15665036 | 0.98 | CA1 (0.39) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL15665037 | 0.98 | CA1 (0.39) | CA1CA2PEPDZDHHC7LTA4H | |
| Trifluoroacetic Acid SCHEMBL29790595 | 0.93 | S1PR1 (0.36) | CA1CA2PEPDLTA4HNOS2 | |
| Trifluoroacetic Acid SCHEMBL31341361 | 0.93 | S1PR1 (0.36) | CA1CA2PEPDLTA4HNOS2 | |
| SCHEMBL1068024 | 0.92 | CA1 (0.38) | CA1CA2PEPDZDHHC7LTA4H | |
| SCHEMBL206673 | 0.92 | CA1 (0.38) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL1068022 | 0.90 | NOS2 (0.39) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL15666248 | 0.90 | NOS2 (0.39) | CA1CA2PEPDZDHHC7LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727546-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | The Global Alliance for TB Drug Development, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025019626-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-2914596-B1 | HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-3030564-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-15 | — | — | EP | disclosed |
| EP-2914596-A1 | HYDROXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-09-09 | — | — | EP | disclosed |
| WO-2015018808-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINECARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | disclosed |
| US-8796305-B2 | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8778964-B2 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-07-15 | — | — | US | disclosed |
| WO-2014068104-A1 | HYDROXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | WO | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | CA1 2481/4885CA2 658/4885PEPD 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.